The Belgian diagnostics group Eurofins Scientific SE has acquired all of the GATC Biotech AG share capital. The parties have agreed not to disclose the purchase price. The transaction still requires the approval of the antitrust authorities.
Eurofins Scientific, with an annual turnover in excess of 2.5 billion euros and a workforce of more than 28,000 in over 310 locations in 39 countries, is a leading international group of laboratories providing a broad range of testing and support services for the pharmaceutical, food, environmental and consumer products industries as well as being a worldwide leader in the bioanalysis field.
GATC, founded in 1990, is one of the top specialists for DNA sequencing inEurope, with over 10,000 clients in the science, industry and healthcare sectors. GATC has particular expertise in sequencing methods (Sanger and NextGeneration Sequencing) and achieves an annual turnover of around 20 million euros at its sites in Constance and Cologne with a staff of about 140 personnel.
The acquisition will further strengthen Eurofins’ technological platform and reflects the group’s committed dynamic growth strategy.
Background to retainer: The GATC transaction was characterized by a very narrow transaction window. AC Tischendorf managed to wrap up the whole transaction in just two weeks and therefore succeed in further consolidating their already excellent client relationship with the buyer. AC Tischendorf have been acting for Eurofins for many years on a regular and comprehensive basis.The law firm has already successfully advised Eurofins on several transactionsin the past, including the acquisition of a group of clinics.
The transaction team of AC Tischendorf consisted of Dr. Sven Tischendorf, MBA (lead management, Corporate/M&A), Ina von Raven,LL.M., Fabian Brocke, LL.M. (both Corporate/M&A), Marcus Columbu (Commercial), Dr. Stephan Schwilden, MBA (employment law) and Dr. Florian Wäßle, LL.M. (IP/IT).